• 医学文献
  • 知识库
  • 评价分析
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
  • 临床诊疗知识库
  • 中医药知识库
  • 机构
  • 作者
热搜词:
换一批
论文 期刊
取消
高级检索

检索历史 清除

医学文献 >>
  • 全部
  • 中外期刊
  • 学位
  • 会议
  • 专利
  • 成果
  • 标准
  • 法规
知识库 >>
  • 临床诊疗知识库
  • 中医药知识库
评价分析 >>
  • 机构
  • 作者
热搜词:
换一批

Endostar combined with chemotherapy for treatment of metastatic colorectal and gastric cancer: a pilot study

摘要:

Background Antiangiogenesis is a promising field of cancer therapy.Endostar,a novel recombinant human endostatin,is one of the few approved drugs acting as angiogenesis inhibitors of cancer in China.However,there are few clinical studies about Endostar in gastrointestinal cancer.This pilot study aimed to evaluate the efficacy and safety of the combination of Endostar and chemotherapy in patients with metastatic colorectal and gastric cancers.Methods From March 2007 to October 2009,23 patients were enrolled.Patients received Endostar intravenously at a dose of 15 mg daily from day 1 to 14 and day 1 to 7 when combined with 3- and 2-week chemotherapy regimens,respectively,which were determined according to patients' previous chemotherapy history.Treatment was repeated until disease progression,unacceptable toxicity or patients' refusal.Results Seven,six and ten patients received Endostar as first-,second- and third-line therapy,respectively.A total of 75 cycles were administered.Twenty-one patients were assessable for responses.The overall response rate and disease control rate were 19.0% and 47.6%,respectively.All the four partial responses were among patients receiving Endostar as first-line therapy,whose response rate was 57.1%.The median time to progression and overall survival were 2.6 months (95% Cl,2.0-3.2 months) and 10.3 months (95% Cl,3.9-16.7 months),respectively.Toxicity was tolerable,with grade 3-4 toxicities observed for leucopenia (30.4%),neutropenia (34.8%),thrombocytopenia (17.4%) and anemia (13.0%).Three patients (13.0%) encountered transient sinus bradycardia with spontaneous remission.Conclusion Endostar combined with chemotherapy is well-tolerated in patients with metastatic colorectal and gastric cancers,and it is relatively effective as a first-line therapy.

更多
作者单位: Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China [1]
期刊: 《中华医学杂志(英文版)》2011年124卷24期 4299-4303页 SCIMEDLINEISTICCSCDBP
分类号: R1
栏目名称: ORIGINAL ARTICLES
DOI: 10.3760/cma.j.issn.0366-6999.2011.24.031
发布时间: 2012-03-06
翻译满意度评价:
提交
  • 浏览:244
  • 下载:16

加载中!

相似文献

  • 中文期刊
  • 外文期刊
  • 学位论文
  • 会议论文

加载中!

加载中!

加载中!

加载中!

特别提示:本网站仅提供医学学术资源服务,不销售任何药品和器械,有关药品和器械的销售信息,请查阅其他网站。

  • 客服热线:4000-115-888 转3 (周一至周五:8:00至17:00)

  • |
  • 客服邮箱:yiyao@wanfangdata.com.cn

  • 违法和不良信息举报电话:4000-115-888,举报邮箱:problem@wanfangdata.com.cn,举报专区

官方微信
万方医学小程序
new翻译 充值 订阅 收藏 移动端

官方微信

万方医学小程序

使用
帮助
Alternate Text
调查问卷